The analysis of European Business Enterprise R&D expenditure in human health activities reveals significant disparities among countries. In 2023, Italy led with 339.06 million euros, followed by Spain and Portugal at 93.21 and 32.88 million euros, respectively. Notable growth was observed in Portugal and Lithuania, with variations of 22.09% and 26.03%. Meanwhile, Germany and Estonia saw no change, while Slovakia experienced a decline of 5.55%. The compound annual growth rate over the past five years indicates substantial increases in some smaller markets which may shift the landscape in future years.
Future trends to watch include:
- Continued strong growth potential in Southern European countries, particularly Portugal and Italy, driven by innovation and investment in health R&D.
- Potential European Union funding shifts that may realign smaller countries like Lithuania and Estonia as emerging players in health sector R&D.
- Strategic investments in technology and collaboration across borders enhancing R&D success rates and efficiencies in larger markets like Germany.
- An increasing focus on digital health technologies, potentially influencing expenditure patterns and priority areas.
Top countries in Business Enterprise R&D Expenditure in Human Health Activities by Country
| # | 9 Countries | Million Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Italy | 339.06 | 2023 | +5.62% | +4.18% | View data |
| 2 | 2 Spain | 93.21 | 2023 | +1.34% | +2.85% | View data |
| 3 | 3 Portugal | 32.88 | 2023 | +16.63% | +22.09% | View data |
| 4 | 4 Finland | 20.75 | 2021 | +58.42% | View data | |
| 5 | 5 Germany | 8.41 | 2023 | +21.77% | View data | |
| 6 | 6 Lithuania | 4.36 | 2023 | -1.38% | +26.03% | View data |
| 7 | 7 Estonia | 1.33 | 2023 | +1.29% | View data | |
| 8 | 8 Latvia | 0.47 | 2023 | +0.21% | +4.81% | View data |
| 9 | 9 Slovakia | 0.31 | 2023 | -6.36% | -5.55% | View data |
